Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease

Renal Failure

Volumn 35, Issue 8, 2013, Pages 1089-1093

  Sengul, Erkan ^a   Duygulu, Gokhan ^a   Dindar, Sevim ^a   Bunul, Fatih ^a  

^a Derince Education and Research Hospital ^*  (Turkey)

Author keywords

Atherosclerosis; Chronic kidney disease; IL 6; Inflammation; Omentin 1

Indexed keywords

INTERLEUKIN 6; OMENTIN 1; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY MASS; CAROTID ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; LECTINS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84881560651     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.817256     Document Type: Article

References (36)

1. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139: 137-147.
2. Locatelli F, Pozzoni P, Tentori F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant. 2003; 18: vii2-9.
3. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000; 15: 454-457.
4. Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC. Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol. 2012; 2012: 691369.
5. Stenvinkel P, Herzog CA. Cardiovascular disease in chronic kidney disease. In Floege J, Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology. 4th ed. Missouri: Elsevier Saunders; 2010: 935-950.
6. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010; 2010: 535918.
7. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004; 110: 3335-3340.
8. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011; 34: 307-310.
9. Hansen T, Ahlström H, Söderberg S, et al. Visceral adipose tissue, adiponectin levels and insulin resistance are related to atherosclerosis as assessed by whole-body magnetic resonance angiography in an elderly population. Atherosclerosis. 2009; 205: 163-167.
10. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006; 290: E1253-E1261.
11. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-a-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol. 2012; 686: 116-123.
12. Xie H, Xie PL, Wu XP, et al. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. Cardiovasc Res. 2011; 92: 296-306.
13. Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012; 4: 37.
14. Auguet T, Quintero Y, Riesco D, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet. 2011; 12: 60.
15. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007; 56: 1655-1661.
16. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010; 88: 29-33.
17. Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008; 57: 801-808.
18. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity. 2011; 19: 1552-1559.
19. El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischemic heart disease. Diabet Med. 2011; 28: 1194-1200.
20. Yoo HJ, Hwang SY, Hong HC, et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011; 10: 103.
21. Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011; 93: 21-25.
22. Zhong X, Zhang HY, Tan H, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011; 32: 873-878.
23. Shibata R, Takahashi R, Kataoka Y, et al. Association of a fatderived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertens Res. 2011; 34: 1309-1312.
24. Alcelik A, Tosun M, Ozlu MF, et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res. 2012; 35: 511-516.
25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35: S64-S71.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419.
27. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
28. Kablak-Ziembicka A, Przewlocki T, Tracz W, et al. Prognostic value of carotid intima-media thickness in detection of coronary atherosclerosis in patients with calcified aortic valve stenosis. J Ultrasound Med. 2005; 24: 461-467.
29. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010; 393: 668-672.
30. Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol. 2011; 165: 789-796.
31. Shaker M, Mashhadani ZI, Mehdi AA. Effect of treatment with metformin on omentin-1, ghrelin and other biochemical, clinical features in PCOS patients. Oman Med J. 2010; 25: 289-293.
32. Moreno-Navarrete JM, Catalán V, Ortega F, et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 2010; 7: 27.
33. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes. 2010; 59: 3023-3031.
34. Slee AD. Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab (Lond). 2012; 9: 36.
35. Yilmaz Y, Yonal O, Kurt R, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol. 2011; 46: 91-97.
36. Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani M. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial. Regul Pept. 2013; 182: 1-6.